Nanoparticle drug formulations (NDFs) allow for local and durable release of cancer
therapeutics, and hold tremendous promise for advancing the efficacy of cancer treatment …

The development of cancer nanotherapeutics has attracted great interest in the recent
decade. Cancer nanotherapeutics have overcome several limitations of conventional …

Nanotherapeutics have improved the quality of life of cancer patients, primarily by reducing
the adverse effects of chemotherapeutic agents, but improvements in overall survival are …

Chemotherapy drugs are cytotoxic to tumor cells, but their lack of specificity leads to a range
of side effects. The off‐target effects of such drugs can be improved through the use of …

The development of therapeutic nanoparticles (TNPs) for cancer treatment is one of the
fastest growing research areas in oncology. Accumulating evidence has shown many …

Cancer is among the leading causes of death worldwide, with the number of new cancer
cases expected to rise to 22 million in the next two decades. Most chemotherapy drugs in …

Nanoparticle-based therapeutics are poised to become a leading delivery strategy for
cancer treatment because they potentially offer higher selectivity, reduced toxicity, longer …

The ability to efficiently deliver a drug or gene to a tumor site is dependent on a wide range
of factors including circulation time, interactions with the mononuclear phagocyte system …

Nanotechnology has emerged as a transformative force in oncology, facilitating
advancements in site-specific cancer therapy and personalized oncomedicine. The …

Nanomedicines for cancer treatment have been studied extensively over the last few
decades. Yet, only five anticancer nanomedicines have received approvals from the United …